ImmuSAFE Instructions

lmmuSAFE™ web applications instructions

To begin generating your report on the ImmuSAFE™ Cloud-based Analysis portal, please visit www.immusafe.sengenics.com and perform the following steps:

ImmuSAFE COVID19 Test Biochip Kit | Sengenics Proteomics | Krex Protein Microarrays

Step 1

Download the “Data Input” and “Sample Manifest” template sheets.

ImmuSAFE COVID19 Test Biochip Kit | Sengenics Proteomics | Krex Protein Microarrays

Step 2

Fill in the “Data Input” sheet with the required information from the .GPR files:
1. Slide ID
2. Block Number
3. Name
4. ID/Protein
5. F635 Median
6. B635 Median
7. B635 SD

ImmuSAFE COVID19 Test Biochip Kit | Sengenics Proteomics | Krex Protein Microarrays

Step 3

Fill in patient specific details in the “Sample Manifest” sheet with the following information :
1. Slide ID
2. Block Number
3. Sample ID
4. Date of Birth
5. ID or MRN Number
6. Gender
7. RT-PCR status
8. Date of Sample collection
9. Date of Sample Run
10. COVID-19 Symptoms
11. Project ID
(Note: Please ensure that the Slide ID and Block Number for both sheets match)

ImmuSAFE COVID19 Test Biochip Kit | Sengenics Proteomics | Krex Protein Microarrays

Step 4

Upload the sheets to the ImmuSAFE™ Cloud-based Analysis portal and key in the requested details for report delivery.

ImmuSAFE COVID19 Test Biochip Kit | Sengenics Proteomics | Krex Protein Microarrays

Step 5

An individual report for each sample will be generated and sent to the email address provided in Step 4.

lmmuSAFE™ utilises Sengenics’ patented KREX™ protein folding technology ensuring that viral antigens are correctly folded, preserving all conformational and linear antibody binding sites. More than ten domains of SARS-CoV-2 Nucleocapsid and Spike proteins including both full-length and numerous truncated versions are used in the tests.

The biochip enables the determination of the target epitopes, titres and immunoglobulin class/sub-class (lgG, lgA, lgM; lgG1-4) of antibodies produced across all stages of COVID-19 infection, from initial exposure, disease development, post-recovery or post-vaccination. lmmuSAFE™ can also enable quantitative assessment of patient response in vaccination trials, including differentiation of whether observed antibody responses are due directly to the vaccine or to prior SARS-CoV-2 exposure.

FEATURED PRODUCTS

IMMUNOME Protein Array

High-throughput autoantibody screening protein array containing 1600+ autoantigens

ImmuSAFE COVID Tests

Contains correctly folded antigens from SARS-CoV-2 and 25 other Corona and Influenza viruses

SEROMAX Blood Collection Kit

Obviates conventional blood draw and cold chain by only requiring a pin-prick of blood

Sengenics - Functional Proteomics | Krex Technology | Protein Microarray Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics UK Registered in England and Wales no. 12889389